Items where authors include "Dalal, S."

Article

Schaefer, R. orcid.org/0000-0003-4733-4692, Donaldson, L., Leus, M. et al. (23 more authors) (2024) Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group. PLOS Global Public Health, 4 (10). e0003878. ISSN 2767-3375

Munir, T., Cairns, D.A. orcid.org/0000-0002-2338-0179, Bloor, A. et al. (29 more authors) (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. ISSN 0028-4793

Hillmen, P., Pitchford, A., Bloor, A. et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Book Section

Rice, B. orcid.org/0000-0002-5416-8058 and Dalal, S. (2022) Chapter 5: Harnessing the strength of routine data for HIV surveillance. In: Dalal, S., (ed.) Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact. World Health Organization , Geneva, Switzerland , pp. 187-224. ISBN 9789240055322

Proceedings Paper

Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. In: Blood. 65th ASH: Annual Meeting & Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , p. 632.